Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2026-01-06 @ 9:29 AM
Study NCT ID:
NCT06809205
Status:
COMPLETED
Last Update Posted:
2025-02-05
First Post:
2025-01-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011470', 'term': 'Prostatic Hyperplasia'}], 'ancestors': [{'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077409', 'term': 'Tamsulosin'}, {'id': 'D000068581', 'term': 'Tadalafil'}], 'ancestors': [{'id': 'D000096926', 'term': 'Benzenesulfonamides'}, {'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D002243', 'term': 'Carbolines'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 95}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-04-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2024-08-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-30', 'studyFirstSubmitDate': '2025-01-24', 'studyFirstSubmitQcDate': '2025-01-30', 'lastUpdatePostDateStruct': {'date': '2025-02-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2025-02-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'IPSS (International Prostate Symptom Score)', 'timeFrame': 'at presentation, 1,3 and 6 month after treatment', 'description': 'The International Prostate Symptom Score (IPSS) is a questionnaire used to assess the severity of symptoms related to the lower urinary tract, often associated with conditions like benign prostatic hyperplasia (BPH) in men. It helps healthcare providers determine the severity of symptoms, monitor changes over time, and guide treatment decisions.\n\nThe IPSS consists of 8 questions, covering symptoms such as:\n\nIncomplete Emptying: Feeling that the bladder is not fully emptied after urination.\n\nFrequency: How often you feel the need to urinate. Intermittency: Whether urine flow starts and stops during urination. Urgency: How urgently you need to urinate. Weak Stream: The strength of the urine stream. Straining: How much effort is needed to urinate. Nocturia: How many times you wake up at night to urinate. Quality of Life: General assessment of how urinary symptoms affect your quality of life.\n\nEach question is rated on a scale from 0 (no symptoms) to 5'}], 'secondaryOutcomes': [{'measure': 'IIEF-5 (five-item International Index of Erectile Function)', 'timeFrame': 'at presentation, 1,3 and 6 month after treatment', 'description': 'The Five-Item International Index of Erectile Function (IIEF-5) is a short, standardized questionnaire used to assess erectile function in men. It is often used to screen for erectile dysfunction (ED) and can help determine its severity.\n\nThe IIEF-5 consists of 5 questions related to the ability to achieve and maintain an erection, as well as overall satisfaction with sexual activity. The questions are scored on a scale from 0 to 5, with a higher score indicating better erectile function.\n\nHere are the five questions:\n\nHow often have you had erections during sexual activity? Scale: 0 (Almost never or never) to 5 (Almost always or always) When you had erections with sexual stimulation, how often were your erections hard enough for penetration? Scale: 0 (Almost never or never) to 5 (Almost always or always) During sexual activity, how often were you able to maintain your erection after you had penetrated? Scale: 0 (Almost never or never) to 5 (Almost always or always) How satisfied have'}, {'measure': 'Q-max (maximum urinary flow rate)', 'timeFrame': 'at presentation, 1,3 and 6 month after treatment', 'description': "The maximum urinary flow rate (Qmax) refers to the highest rate at which urine is expelled from the bladder during urination. It is commonly measured during a uroflowmetry test, which is a diagnostic procedure used to evaluate the efficiency of the urinary system.\n\nHow it's measured:\n\nA person is asked to urinate into a device that records the volume and flow rate of urine over time.\n\nThe test measures the peak flow rate, which is the fastest rate at which urine is being passed during the process.\n\nIt's typically expressed in milliliters per second (mL/s).\n\nWhat the results mean:\n\nNormal Qmax: For men, a typical normal maximum urinary flow rate is usually between 15 and 25 mL/s. In women, normal values can range slightly, depending on factors like age, but are often similar.\n\nLow Qmax: A flow rate lower than normal could indicate an obstruction or narrowing in the urinary tract, bladder dysfunction, or conditions such as benign prostatic hyperplasia (BPH) in men or pelvic floor dysfunctio"}, {'measure': 'PVR (post-void residual urine)', 'timeFrame': 'at presentation, 1,3 and 6 month after treatment', 'description': 'it is a measure of post-void residual urine in bladder using ultrasound'}, {'measure': 'QoL (quality of life)', 'timeFrame': 'at presentation, 1,3 and 6 month after treatment', 'description': 'The QoL Question:\n\nIn the IPSS, there is a single question that asks:\n\n"If you were to spend the rest of your life with your urinary condition, how would you feel about that?"\n\nPatients rate their quality of life on a scale from 0 to 6, where:\n\n0 = "Delighted"\n\n1. = "Pleased"\n2. = "Mostly satisfied"\n3. = "Mixed"\n4. = "Mostly dissatisfied"\n5. = "Very dissatisfied"\n6. = "Terrible" This score helps healthcare providers understand how bothersome the symptoms are, and it contributes to determining the need for treatment.\n\nSignificance of the QoL Score:\n\nLow QoL Score (0-2): Indicates that the patient is generally satisfied with their condition or feels only mild disruption to their life. This might suggest that treatment isn\'t urgently needed, or that the symptoms are not significantly affecting their daily activities.\n\nModerate QoL Score (3-4): Suggests that the symptoms are having a moderate impact on daily life, and treatment may be considered to alleviate the burden.\n\nHigh QoL Score (5-6): Indica'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Tamsulosin, tadalafil, BPH and LUTS'], 'conditions': ['BPH with Other Lower Urinary Tract Symptoms']}, 'referencesModule': {'references': [{'pmid': '25613154', 'type': 'BACKGROUND', 'citation': 'Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19.'}, {'pmid': '29394114', 'type': 'BACKGROUND', 'citation': 'MacDonald R, Brasure M, Dahm P, Olson CM, Nelson VA, Fink HA, Risk MC, Rwabasonga B, Wilt TJ. Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male. 2019 Mar;22(1):1-11. doi: 10.1080/13685538.2018.1434503. Epub 2018 Feb 2.'}, {'pmid': '32558340', 'type': 'BACKGROUND', 'citation': 'Morton A, Williams M, Perera M, Teloken PE, Donato P, Ranasinghe S, Chung E, Bolton D, Yaxley J, Roberts MJ. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int. 2020 Sep;126 Suppl 1:18-26. doi: 10.1111/bju.15098. Epub 2020 Jun 17.'}, {'pmid': '31961963', 'type': 'BACKGROUND', 'citation': 'Yamanishi T, Kaga K, Sakata K, Yokoyama T, Kageyama S, Fuse M, Tokunaga S. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020 Feb;39(2):804-812. doi: 10.1002/nau.24285. Epub 2020 Jan 21.'}, {'pmid': '16465187', 'type': 'BACKGROUND', 'citation': 'Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006 Feb;147 Suppl 2(Suppl 2):S88-119. doi: 10.1038/sj.bjp.0706619.'}], 'seeAlsoLinks': [{'url': 'https://pubmed.ncbi.nlm.nih.gov/25613154/', 'label': 'EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/29394114/', 'label': 'Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male.'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32558340/', 'label': 'Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data.'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/31961963/', 'label': 'A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/16465187/', 'label': 'Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.'}]}, 'descriptionModule': {'briefSummary': 'Abstract:\n\nObjective: To examine the influence of tadalafil and tamsulosin versus their combinations in the treatment of lower urinary tract symptoms in mildly enlarged prostates below 40 ml in volume.\n\nMaterials and methods: A prospective randomized study was done at Fayoum and Beni-Suef University Hospitals in Egypt from December 2022 to August 2023. A total of 95 male participants aged over 45 years, all presenting with mild to intense lower urinary tract symptoms, were enrolled. Participants were randomized into three groups: Group A was administered Tamsulosin (0.4 mg per day), Group B was administered tadalafil (5 mg per day), and Group C was administered a mixture of both medications. The study assessed multiple parameters, the primary endpoint parameter was the International Prostate Symptom Score (IPSS) and the other secondary parameters were the five-item International Index of Erectile Function (IIEF-5), maximum urinary flow rate (Q-max), post-void residual urine (PVR), and the quality of life (QoL). At baseline, these parameters were assessed, followed by evaluations at 1, 3, and 6 months after treatment.\n\nKey words. Tamsulosin, tadalafil, BPH and LUTS.', 'detailedDescription': "Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 ml: A Prospective Comparative Study.\n\nMohamed Mahmoud Dogha\\*1, Mahmoud Shoukry ElAdawy¹, Rabie M Ibrahim², Ahmed Yousef2, ,Samia Heikal3, Mahmoud AbdElhamid4, Ahmed Abdalgalil1, Hossam Shaker¹.\n\n1. Department of Urology, Faculty of Medicine, Fayoum University, Egypt\n2. Department of Urology, Faculty of Medicine, Beni-suef University, Egypt\n3. Diagnostic Radiology Department, National Cancer Institute, Cairo University\n4. Department of Urology, Faculty of Medicine, Cairo University, Egypt\n\n \\*Email: mma16@fayoum.edu.eg\n\n Introduction:\n\n Lower urinary tract symptoms (LUTS) are frequently triggered by benign prostatic enlargement (BPE), such as storage symptoms like nocturia, frequency, and urgency, along with voiding symptoms like hesitancy, weak flow, and straining, all of which can substantially impact the total quality of life for a patient. \\[1, 2\\] Treatment options for LUTS related to BPE include surgical intervention, pharmacotherapy (such as 5-alpha reductase inhibitors, phosphodiesterase 5 inhibitors, alpha blockers, and phytotherapies) and other approaches. \\[3, 4\\] alpha blockers work by reducing prostate tone through the inhibition of noradrenaline's influence on smooth muscle cells in the prostate. \\[5\\] Although the complete clinical effects of alpha blockers may take a few weeks to become evident, notable improvements can often be seen within hours to days. \\[6\\] These medications are effective in alleviating both storage and voiding LUTS without reducing prostate size, although they tend to be more effective in patients with a prostate size of lower than 40 ml. \\[7-10\\] Despite these advancements in the Qmax and the IPSS can be sustained for at least four years with alpha blocker therapy. phosphodiesterase 5 inhibitors reduce smooth muscle tone in the urethra, prostate, and detrusor, and their chronic use may raise oxygenation, and blood flow, and potentially diminish chronic inflammation in the lower urinary tract. However, the precise way in which they influence LUTS is still not well understood. \\[11-13\\] Our study aimed to examine the efficacy of tamsulosin versus tadalafil, and their combination; in treating LUTS/BPE in individuals with a prostate size ≤ 40 ml.\n\n Materials and methods:\n\n Our prospective randomized clinical assessment was performed from December 2022 to August 2023 at the Urology Department of Fayoum and Beni-suef University Hospitals Randomization was carried out using a sealed envelope method. The Review Board, an ethical commission, received approval (approval number: R 450) from the hospital ethics committee at the Fayoum University Faculty of Medicine. After receiving a detailed explanation of the study's objectives, participants were made aware of the purpose and benefits of the analysis. The participants in the study provided their consent willingly. Moreover, written consent was secured in advance. The confidentiality of the information collected was assured to the participants. Inclusion criteria were male patients aged ≥ 45years with prostate volume less than 40 ml, with mild to intense LUTS/BPH as regard to IPSS.The exclusion criteria included a prostate-specific antigen (PSA) level exceeding 4 ng/mL, a prostate volume exceeding 40 ml, an amount of remaining urine of 300 mL or more, the utilize of 5-alpha reductase inhibitors (5-ARIs) in the past three months, a history of prostate surgery or malignancy, urethral stricture, urinary retention, bladder stones, neurological diseases affecting bladder function, cardiovascular diseases, and treatment with nitrates. Patients were divided into three groups: group A was administered 0.4 mg tamsulosin per day, group B was administered tadalafil 5mg daily, and group C was administered a mixture of both tadalafil and tamsulosin. Each patient underwent assessments at four distinct intervals: at presentation and after 1, 3, and 6 months of treatment. At the initial presentation, comprehensive assessments were performed, while follow-up visits included evaluations of the IIEF-5, IPSS, uroflowmetry, PVR and IPSS QoL scores. The results from the three groups were recorded at all four visits and subsequently compared and analyzed statistically.All ultrasounds were performed by the same radiologist to eliminate the bias of different radiology operators Statistical methods: G \\* power was used to determine a minimum sample size of 90. The target sample size was computed with an alpha value of 0.05, an effect size of 0.25, and a power of study of 0.8. The data were analyzed using SPSS (Statistical Package for the Social Sciences) version 28 (IBM Corp., Armonk, NY, USA). The mean and standard deviation of the data served as a summary. Groups were compared using analysis of variance (ANOVA), followed by a post-hoc multiple comparisons test (Chan, 2003). Data was double checked for normality using normality plots and Shapiro Wilk test and proved not to be deviated from normal distribution. According to \\[14\\], statistical significance was defined as a p-value less than 0.05.\n\n Declarations Ethics approval and consent to participate: The Review Board, an ethical commission, received approval (approval number: R 450) from the hospital ethics committee at the Fayoum University Faculty of Medicine in accordance with the declaration of Helsinki. And every participant provided a cleared and detailed consent.\n\n Conflict of Interest: None. Funding: None.\n\n Authors' contributions:\n\n Mohamed Mahmoud Dogha conducted conception and design of the study. Mahmoud S. ElAdawy and Mahmoud AbdElhamid performed interpretation of data, work design. Hossam shaker, Samia Heikal and Ahmed Abdalgalil did conception and design of the study, drafted the manuscript, interpretation of data. Rabie M. Ibrahim and Ahmed Yousif drafted the manuscript, Data analysis\n\n Abbreviations:\n5. ARIs: 5-alpha reductase inhibitors BPE: Benign prostatic enlargement IEFF-5: International Index of Erectile Function 5 items IPSS: international prostate symptom score LUTS: Lower urinary tract symptoms PDE5Is: phosphodiesterase type 5 inhibitors PSA: Prostate-specific antigen Qmax: maximum urinary flow rate QoL: quality of life"}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '45 Years', 'genderBased': True, 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Inclusion criteria were male patients aged ≥ 45years with prostate volume less than 40 ml, with mild to intense LUTS/BPH as regard to IPSS.\n\nExclusion Criteria:\n\n* The exclusion criteria included a prostate-specific antigen (PSA) level exceeding 4 ng/mL, a prostate volume exceeding 40 ml, an amount of remaining urine of 300 mL or more, the utilize of 5-alpha reductase inhibitors (5-ARIs) in the past three months, a history of prostate surgery or malignancy, urethral stricture, urinary retention, bladder stones, neurological diseases affecting bladder function, cardiovascular diseases, and treatment with nitrates.'}, 'identificationModule': {'nctId': 'NCT06809205', 'briefTitle': 'Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study', 'organization': {'class': 'OTHER', 'fullName': 'Fayoum University Hospital'}, 'officialTitle': 'Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study', 'orgStudyIdInfo': {'id': 'R 450'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group A', 'description': 'Group A was administered Tamsulosin (0.4 mg per day)', 'interventionNames': ['Drug: Tamsulosin 0.4 mg']}, {'type': 'EXPERIMENTAL', 'label': 'Group B', 'description': 'Group B was administered tadalafil (5 mg per day)', 'interventionNames': ['Drug: Tadalafil 5mg']}, {'type': 'EXPERIMENTAL', 'label': 'group c', 'description': 'administered tadalafil and tamsulosin 0.4 mg', 'interventionNames': ['Drug: Tamsulosin and Tadalafil']}], 'interventions': [{'name': 'Tamsulosin 0.4 mg', 'type': 'DRUG', 'otherNames': ['group A'], 'description': 'administered tamsulosin 0.4 mg', 'armGroupLabels': ['Group A']}, {'name': 'Tadalafil 5mg', 'type': 'DRUG', 'otherNames': ['group B'], 'description': 'administered tadalafil 5 mg', 'armGroupLabels': ['Group B']}, {'name': 'Tamsulosin and Tadalafil', 'type': 'DRUG', 'otherNames': ['Group C'], 'description': 'administered tamsulosin 0.4 mg plus tadalafil 5 mg', 'armGroupLabels': ['group c']}]}, 'contactsLocationsModule': {'locations': [{'zip': '63514', 'city': 'Al Fayyum', 'state': 'Fayoum Governorate', 'country': 'Egypt', 'facility': 'Mohamed Mahmoud Dogha', 'geoPoint': {'lat': 29.30995, 'lon': 30.8418}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fayoum University Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'lecturer of urology- faculty of medicine- fayoum university', 'investigatorFullName': 'Mohamed Mahmoud Dogha', 'investigatorAffiliation': 'Fayoum University Hospital'}}}}